Compare Abbott Laboratories (ABT) vs Target Corporation (TGT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Target Corporation — how do they compare? Abbott Laboratories trades at $95.63 (market cap $166.94B), while Target Corporation trades at $132.63 (market cap $57.93B). The key difference: Abbott Laboratories is far larger — about 2.9× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| ABT | TGT | |
|---|---|---|
Market Cap | $166.94B | $57.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $141.19 |
52-Week Low | $82.57 | $83.68 |
Enterprise Value | $193.69B | $73.23B |
Dividend Yield | 2.63% | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Target trades at $127.55, down 2.04% today, with technical indicators showing bearish momentum. The stock maintains solid fundamentals with a P/E of 16.66 and net income margin of 3.24%, supported by three consecutive quarterly EPS beats. Recent news highlights Target's marketplace expansion and consumer resilience focus amid retail sector volatility.
The outlook remains balanced with a consensus price target of $137 offering 7.4% upside potential, though bearish technical signals and competitive pressures pose risks. Strong cash flow generation and dividend payments provide shareholder stability while execution on growth initiatives will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
